On January 13, 2026, the United States Department of Justice (DOJ) announced that Atlantic Biologicals Corporation, a Miami-based pharmaceutical distributor, paid a $450,000 criminal penalty and entered into a two-year deferred prosecution agreement. The settlement resolves the government’s allegations
“Breaking news: Controlled substance compliance failures rock major corporation.”
This is the kind of headline that doesn’t just attract attention. It plants doubt in your whole organization.
Imagine this:
A distributor notices unusual order growth for a controlled substance.
I know it can be said about many areas of the law; however, the statue, regulations, and administrative caselaw governing controlled substances is truly a different animal. I frequently get calls from attorneys seeking advice on matters involving Drug Enforcement
I am extremely excited to announce the latest addition to the Controlled Substance Solutions (CSS) software suite – ARCOS IQ.
So, what is ARCOS IQ? I am glad you asked. ARCOS IQ is a user-friendly, one-stop shop, for your ARCOS
(If this song is stuck in your head all day long, you are welcome.)
As my loyal readers are aware (too Bridgerton?), customer due diligence obligations, especially for distributors and manufacturers, have significantly evolved over the past several years.
Today, the Drug Enforcement Administration announced the revocation of Coconut Grove Pharmacy’s DEA registration.
DEA issued an Order to Show Cause and Immediate Suspension of Registration back in September 2022, premised on Coconut Grove’s alleged failure to identify, resolve,
In a highly regulated industry, such as controlled substance distribution, having clarity of regulatory requirements facilitates implementation and execution of an effective compliance program. Uncertainty on expectations from regulators and/or significant “grey area” in compliance requirements present additional risk for
In a highly regulated industry, such as controlled substance distribution, having clarity of regulatory requirements facilitates implementation and execution of an effective compliance program. Uncertainty on expectations from regulators and/or significant “grey area” in compliance requirements present additional risk for
There is legislation making the rounds on Capitol Hill that seeks to provide clarity regarding the process for reviewing orders for controlled substances to determine if an order is a “suspicious order” that should be reported to the Drug Enforcement
There is legislation making the rounds on Capitol Hill that seeks to provide clarity regarding the process for reviewing orders for controlled substances to determine if an order is a “suspicious order” that should be reported to the Drug Enforcement
